The company builds on Premier's eight-year track record of direct contracting for healthcare supplies and extends existing programmes that are successfully providing uninterrupted access to more than 91 shortage stock keeping units.
This new company, ProvideGx, provides a vehicle for Premier to invest in innovative new business models and partnerships to address drug shortages, including partnering with quality generic drug manufacturers that can supply shortage products, co-funding the development of affordable products that address specific market needs, and securing contracts for active pharmaceutical ingredients to ensure a continuous supply as well as strategic sourcing agreements.
ProvideGx has already partnered with five generic manufacturers to address a targeted pipeline of 60 crucial drugs, and expects to begin marketing additional shortage products next month, pending approval by the US Food and Drug Administration.
According to the University of Utah Drug Information Service, 224 vital medications are in current shortage nationwide, including antimicrobials, cardiovascular drugs, sedation medications, electrolytes, nutritional supplements and chemotherapy drugs.
As a result of these persistent shortages, 96% of health systems report that securing an adequate source of supply is a near constant challenge.
ProvideGx is guided by 31 Premier member health systems and the company's National Pharmacy Committee, representing more than 1,000 hospitals across the nation.
Revenues from the new company are not expected to materially impact Premier FY 2019 results.
Premier Inc. (NASDAQ: PINC) is a healthcare improvement company, uniting an alliance of more than 4,000 US hospitals and health systems and approximately 165,000 other providers and organizations to transform healthcare.
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial